In the 2nd-line aflibercept/FOLFIRI vs FOLFIRI study (Van...

In the 2nd-line aflibercept/FOLFIRI vs FOLFIRI study (Van Cutsem), the FOLFIRI arm of 614 pts received 6127 cycles of treatment - a mean of 10.0 cycles per patient.

By 28/11/13, the mean treatment cycles across both ACL arms was 4500/395, or 11.4 cycles per patient.... and they were still continuing to treat patients.

If the PhIII FOLFIRI arm is reflected by the Van Cutsem trial control arm, that would suggest that mean cycles per patient for HA-I would be at least 13, or >30% more doses of HA-I compared to irinotecan.  Not hard to miss if you have to supply the drug!

Of course, that's considering the mean not the median, and it's the median outcome that we're looking for.   But at least it's pointing in the right direction.